Generic Name and Formulations:
Sodium hyaluronate 5000 23mg/mL; viscoelastic soln for intraocular use.
Indications for HEALON5:
Inject through a fine cannula into the eye. Amount varies depending on surgery, repeated inj may be required. One syringe of 0.6mL is usually sufficient in anterior segment surgery.
Single use only; reuse may cause inflammatory reaction. Glaucoma; consider prophylactic pressure-lowering treatment. Complete removal of soln necessary to avoid intraocular pressure peaks post-op.
Ophthalmic viscosurgical device.
Incompatibility, resulting in opalescence, between sodium hyaluronate and solutions containing quaternary ammonium ions (eg, detergents, benzalkonium chloride).
Transient rise in intraocular pressure, myopic shift (if product not completely removed).
Sign Up for Free e-newsletters
- Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Handling Chemotherapy Premedications
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
- Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer
- Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|